Rhythm Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
I'm one of the biotechnology analysts at Morgan Stanley, David Lebowitz. And I have with me on the stage from Rhythm Pharmaceuticals, CEO, Keith Gottesdiener. I'm sorry.
No problem, no one ever uses my last name for exactly that reason.
I'll call you Keith G. Rhythm is a company that develops therapies for ultra-rare forms of genetic obesity. If you could, I guess, give us a top level just on the company and bring us up to speed on the recent updates.
Sure. So Rhythm is a company, as David said, that focuses on rare genetic causes of obesity, and we are focused on the pathway in the brain called the melanocortin-4, MC4 pathway, which is probably the key pathway in the brain that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
